ERBB2 and neoplasm: Most studies and meta-analyses discussing the pCR rate reveal that incorporating anti-HER2 therapy in neoadjuvant regimens shows the pCR rate to be higher in HER2+ and HR status negative patients [6,10]; however, other risk factors, such as tumor size, status of lymph node involvement and clinical stage, which may or may not be related to pCR rate, are controversial.